{"id":9577,"date":"2023-11-14T15:33:55","date_gmt":"2023-11-14T12:33:55","guid":{"rendered":"https:\/\/cis.actionprgroup.com\/?post_type=case-study&#038;p=9577"},"modified":"2023-11-16T09:46:26","modified_gmt":"2023-11-16T06:46:26","slug":"online-participation-of-kz-media-in-boehringer-ingelheim-regional-press-conference","status":"publish","type":"case-study","link":"https:\/\/cis.actionprgroup.com\/case-study\/online-participation-of-kz-media-in-boehringer-ingelheim-regional-press-conference\/","title":{"rendered":"participation\u00a0of KZ media in regional press\u00a0conference"},"content":{"rendered":"\n<p style=\"font-size:30px\"><strong>challenge<\/strong>:<\/p>\n\n\n\n<p>To mark empagliflozin&#8217;s approval in the EU for the\u00a0treatment of adults with chronic kidney disease, Boehringer\u00a0Ingelheim has held a press conference in its Regional Vienna\u00a0Center with the goal to secure participation of media from the\u00a0whole region, including Kazakhstan.\u00a0<\/p>\n\n\n\n<p style=\"font-size:30px\"><strong>approach<\/strong>:<\/p>\n\n\n\n<p>In order to have Kazakhstani tier1 medical media present at the&nbsp;event, Action team has undertaken the following activities:&nbsp;\u200b<\/p>\n\n\n\n<ul>\n<li>Selection and invitation of 2 tier1 media for online&nbsp;participation\u200b<\/li>\n\n\n\n<li>Arrangement of simultaneous translation during the event\u200b<\/li>\n\n\n\n<li>Translation of press kit, including press text, infographics,&nbsp;speakers bios\u200b<\/li>\n\n\n\n<li>Translation to RU and KZ languages of press conference&nbsp;summary\u200b<\/li>\n\n\n\n<li>Provision of necessary additional information upon journalists&nbsp;requests\u200b<\/li>\n\n\n\n<li>Fact-checking and confirming articles generated after the&nbsp;press conference with BI KZ team\u200b<\/li>\n\n\n\n<li>Result: dedicated articles on&nbsp;<a href=\"https:\/\/pharmnewskz.com\/ru\/article\/empagliflozin-jardiance-teper-odobren-i-dlya-pacientov-s-hronicheskoy-boleznyu-pochek_21726\" target=\"_blank\" rel=\"noreferrer noopener\">pharmnewskz.com<\/a>&nbsp;and&nbsp;<a href=\"https:\/\/pharm.reviews\/ru\/stati\/vse-o-lekarstvakh\/item\/8867-odobreno-novoe-pokazanie-empagliflozina-lechenie-khronicheskoj-bolezni-pochek\" target=\"_blank\" rel=\"noreferrer noopener\">pharm.reviews<\/a>\u200b<\/li>\n<\/ul>\n","protected":false},"featured_media":9615,"template":"","tags":[],"region":[],"expertise":[149],"industry":[190],"_links":{"self":[{"href":"https:\/\/cis.actionprgroup.com\/wp-json\/wp\/v2\/case-study\/9577"}],"collection":[{"href":"https:\/\/cis.actionprgroup.com\/wp-json\/wp\/v2\/case-study"}],"about":[{"href":"https:\/\/cis.actionprgroup.com\/wp-json\/wp\/v2\/types\/case-study"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cis.actionprgroup.com\/wp-json\/wp\/v2\/media\/9615"}],"wp:attachment":[{"href":"https:\/\/cis.actionprgroup.com\/wp-json\/wp\/v2\/media?parent=9577"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cis.actionprgroup.com\/wp-json\/wp\/v2\/tags?post=9577"},{"taxonomy":"region","embeddable":true,"href":"https:\/\/cis.actionprgroup.com\/wp-json\/wp\/v2\/region?post=9577"},{"taxonomy":"expertise","embeddable":true,"href":"https:\/\/cis.actionprgroup.com\/wp-json\/wp\/v2\/expertise?post=9577"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/cis.actionprgroup.com\/wp-json\/wp\/v2\/industry?post=9577"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}